ArticlePPAR research2008
The Role of the PAX8/PPARgamma Fusion Oncogene in Thyroid Cancer.
Article in PPAR research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 54 citations in OpenAlex.
- Pathogenesis of Thyroid Cancer with Particular Emphasis on the Role of AnoikisJournal of clinical research in pediatric endocrinology · 2026Review
- Single-cell transcriptomic analysis identifies decreasedTranslational cancer research · 2026Article
- Targeting the Warburg Effect in Anaplastic Thyroid Carcinoma: Metabolic Vulnerabilities and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Molecular Landscape and Therapeutic Strategies in Pediatric Differentiated Thyroid Carcinoma.Endocrine reviews · 2025Review
- Review
- Paired box 8 facilitates the c-MYC related cell cycle progress in TP53-mutation uterine corpus endometrial carcinoma through interaction with DDX5.Cell death discovery · 2022Article
- The Significance of PAX8-PPARContrast media & molecular imaging · 2022Article
- PAX8 as a Potential Target for Ovarian Cancer: What We Know so Far.OncoTargets and therapy · 2022Review
- Review
- Genetic differences in follicular thyroid carcinoma between Asian and Western countries: a systematic review.Gland surgery · 2020Review
- Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer.Endocrine · 2019Article
- Rapid methods to create a positive control and identify theOncotarget · 2018Article
- A Concise Atlas of Thyroid Cancer Next-Generation Sequencing Panel ThyroSeq v.2.Molecular imaging and radionuclide therapy · 2017Article
- Thyroid transcription factors in development, differentiation and disease.Nature reviews. Endocrinology · 2015Review
- Molecular pathways associated with aggressiveness of papillary thyroid cancer.Current genomics · 2014Article
- Prognostic biomarkers in thyroid cancer.Virchows Archiv : an international journal of pathology · 2014Review
- Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer.Journal of oncology · 2014Review
- Candidate agents for papillary thyroid cancer identified by gene expression analysis.Pathology oncology research : POR · 2013Article
- Molecular pathogenesis and mechanisms of thyroid cancer.Nature reviews. Cancer · 2013Review
- Detection of PAX8/PPARG and RET/PTC rearrangements is feasible in routine air-dried fine needle aspiration smears.Thyroid : official journal of the American Thyroid Association · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Thyroid cancer is uncommon and exhibits relatively low mortality rates. However, a subset of patients experience inexorable growth, metastatic spread, and mortality. Unfortunately, for these patients, there have been few significant advances in treatment during the last 50 years. While substantial advances have been made in recent years about the molecular genetic events underlying papillary thyroid cancer, the more aggressive follicular thyroid cancer remains poorly understood. The recent discovery of the PAX8/PPARgamma translocation in follicular thyroid carcinoma has promoted progress in the role of PPARgamma as a tumor suppressor and potential therapeutic target. The PAX8/PPARgamma fusion gene appears to be an oncogene. It is most often expressed in follicular carcinomas and exerts a dominant-negative effect on wild-type PPARgamma, and stimulates transcription of PAX8-responsive promoters. PPARgamma agonists have shown promising results in vitro, although very few studies have been conducted to assess the clinical impact of these agents.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.